Abstract: The disclosure provides microbial compositions (e.g., compositions comprising one or more microbes or protein components thereof), that can be administered to subjects to confer beneficial effects. Disclosed compositions can, for example, be useful in reducing visceral hypersensitivity, or pain in response to colorectal distension.

Abstract: Provided herein are methods and compositions comprising microbial populations with increased tolerability and improved shelf life. Disclosed, herein, in some aspects, is a composition comprising at least one powdered microbial population, lactate, and trehalose. In some embodiments, the lactate is a lactate salt. In some embodiments, the lactate is sodium lactate. In some embodiments, the lactate and trehalose are present in sufficient amount to act as a cryoprotectant.

Abstract: The disclosure provides compositions and methods for therapeutic administration of the compositions to treat comorbidities associated with gut dysbiosis. The disclosure also provides compositions and methods for increasing engraftment of administered microbes. The disclosure also provides methods for stool sample collection.

Abstract: The present disclosure provides a method for formulating a composition of isolated and purified microbes. The present disclosure provides methods for formulating a composition for administration to a subject in need thereof. The method can comprise obtaining a mixture that is substantially dry and comprises about 10% or less residual moisture. The mixture can comprise a population of isolated and purified microbes and a pharmaceutically acceptable carrier. The population can comprise one or more obligate anaerobes that are oxygen-stable. The methods can further comprise encapsulating said mixture in an enteric-coated capsule for delivery to said subject.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The disclosure provides compositions and methods for the treatment of skin disorders using microbial compositions to a subject.

Abstract: Novel compounds and the novel use a class of previously identified small molecules for the inhibition of biofilm formation. Inhibition of biofilm formation can play a very important role in contributing to pathogenicity. Bacteria in the biofilm state have been shown to be 10-10,000-fold less susceptible to antibiotic treatment. Estimations made by the Centers for Disease Control (CDC) and the National Institutes of Health (NIH) attribute 65% to 80% of human infections as biofilm mediated. Consequently, biofilm formation is often responsible for chronic infections due to bacterial persistence despite antibiotic treatment.